

Case Report

COVID-19 and Pulmonary Tuberculosis Coinfection in a Moroccan Patient with Pulmonary Embolism: A Case Report and Literature Review

Imane Zouaki , **Zakaria Chahbi**, **Mohamed Raiteb**, and **Mohamed Zyani**

Department of Internal Medicine, Avicenne Military Hospital, Marrakech, Morocco

Correspondence should be addressed to Imane Zouaki; imane.zouaki@edu.uca.ma

Received 14 December 2021; Revised 22 May 2022; Accepted 23 June 2022; Published 30 July 2022

Academic Editor: Mohd Adnan

Copyright © 2022 Imane Zouaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Emerging cases of coinfection of coronavirus disease 2019 (COVID-19) and tuberculosis (TB), although rare, have attracted the attention of health systems around the world and have arisen many concerns about the diagnosis, treatment, and prognosis of this coinfection especially in high TB burden countries. Here, we report a rare case and, to the best of our knowledge, the first reported case in Morocco of simultaneous diagnosis of an active pulmonary TB infection and a COVID-19 pneumonia. We present a case of a sixty-seven-year-old male patient who was admitted to our COVID-19 emergency department with a diagnosis of COVID-19 pneumonia, confirmed by nasopharyngeal swab's polymerase chain reaction (PCR) for detection of SARS-CoV-2. The atypical radiological findings suggested a TB coinfection which was later confirmed by sputum cultures and Xpert MTB/Rif assay. The patient also presented some complications including thrombosis of the left leg, pulmonary embolism and inaugural ketosis. Treatment was administered as per local protocols: broad spectrum antibiotics, corticosteroids, fixed dose-combination of antituberculosis treatment along with hydration and insulin therapy for ketosis treatment and anticoagulation. The patient was discharged after twenty-three days of hospitalization. Due to the currently limited data, further studies are necessary to establish any possible correlation between COVID-19 infection and the progression of a latent and/or the severity of an active TB infection.

1. Introduction

The coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still spreading across the world since its start on December 2019 in Wuhan city, China, and then declared a pandemic by the WHO on March 2020 [1]. The clinical features are dominated by respiratory and flu-like symptoms such as fever, cough, and fatigue. Meanwhile, tuberculosis is still a global burden affecting millions of people every year with the highest mortality rate of any infectious disease [2]. The concurrence of these two pandemics has arisen many concerns in terms of clinical management, differential diagnosis, treatment, and prognosis, especially in high TB burden countries [3]. There is a scarcity in the current literature concerning cases of coinfection of COVID-19 and TB. Here, we report a rare case of simultaneous diagnosis of an active pulmonary TB

infection and COVID-19 pneumonia with thrombotic complications.

2. Case Presentation

On December 30th, 2020, a sixty-seven-year-old Caucasian male, with no medical or surgical history, presented to our emergency COVID-19 department with persistent dyspnea at rest, along with chest pain, and a persistent cough initially dry becoming productive fifteen days before admission, showing no improvement on clavulanic acid-amoxicillin taken by the patient on self-medication, in a context of fever and night sweats, and deterioration of general status including a weight loss of 10 kg, fatigue, and anorexia. However, the patient had not shown any signs of otorhinopharyngeal viral infection (no anosmia, no taste alteration, no sore throat, and no rhinitis) and had not reported any known close contact with a COVID-19 except




FIGURE 1: CT scan images showing foci of pulmonary condensation and cavitations of the right upper lobe with diffused ground-glass opacities and multiple bilateral foci of nodules and micronodules suggesting CO-RADS 5 with signs of active tuberculosis.

that his son had been treated for pulmonary TB infection a year earlier.

Upon his admission, physical examination revealed a conscient bedridden patient, febrile at 38°C, tachypneic at 30 cpm, saturation levels at 86% on ambient air, tachycardic at 100 bpm, and normotensive with bilateral rhonchi, a swollen painful left leg with positive Homans' sign and vesicular eruption on his abdomen. On another note, his admission's capillary blood glucose was as high as 4 g/l and his urine strip revealed 2 positives for ketones and 2 positives for glucose, thus revealing an inaugural diabetic ketosis. His EKG and cardiac enzymes were normal.

His laboratory findings showed an elevated white blood cells count (10240/ml) (normal: 7000–10000/ml) with high neutrophilic count, a microcytic hypochromic anemia at 10.7 (normal: 13–18 mg/dl), lymphocytopenia at 710 (normal: 1500–4000/mL), an elevated C-reactive protein at 208 (normal: <5 mg/l), normal procalcitonin level 0.26 (normal <5), elevated lactate dehydrogenase at 371 (normal: 135–225 U/L), elevated ferritin at 764 ng/ml (normal: 30–400 ng/ml), blood sugar at 2.29 g/l, and bicarbonates at 22.75 (normal: 22–30). His renal and liver full workup was normal. HIV and other viral serologies also came back negative. His chest computed tomography (CT) scan showed foci of pulmonary consolidation with diffused ground-glass opacities and

multiple bilateral nodules and micronodules all in favor of a CO-RADS 5 with signs of active tuberculosis (Figure 1).

His nasopharyngeal swab for COVID-19 reverse transcriptase-polymerase chain reaction (RT-PCR) came back positive, thus confirming a COVID-19 infection. Also, his sputum for MTB PCR was positive with no rifampicin resistance detected revealing a concomitant infection with *Mycobacterium tuberculosis*. A venous doppler ultrasound of his left leg revealed a total thrombosis of the superficial femoral, popliteal, and sural veins.

The patient was admitted to one of our COVID-19 isolation units and was put under oxygenotherapy via a high flow nasal cannula at 6 liters/min. He was started on broad spectrum antibiotics (2 g of ceftriaxone) for 10 days, corticosteroids (methylprednisolone) 80 mg for 5 days, 40 mg of prednisolone orally, a fixed dose-combination of antituberculosis treatment (isoniazid + rifampicin + pyrazinamide + ethambutol), and anticoagulation with low-molecular weight heparin enoxaparin at 0.6 IU*2 per day and was prescribed support stockings. Intravenous hydration was started as per ketosis correction protocol with correction of hydroelectrolytic disorders and intravenous and then subcutaneous insulin therapy with the following regimen: basal insulin in the evening with boluses of rapid insulin




FIGURE 2: CT scan images showing bilateral micronodules and bronchial dilation in the right upper lobe with parenchymatous opacification. Endoluminal defects of the left pulmonary base suggesting a pulmonary embolism with signs of active TB infection.

three times a day, depending on the patient's capillary blood sugar.

The evolution was favorable with apyrexia on the second day of treatment, the oxygenotherapy was discontinued progressively over 10 days, the patient's COVID-19 PCR came back negative on day 15th of his admission, and his chest CT scan showed endoluminal defects of the segmental arteries of the left pulmonary base, focal cystic dilatation of the upper right lobe with focal parenchymatous consolidation, multiples bilateral micronodules, and lymphadenopathy in Baret's compartment all in favor of a pulmonary embolism with signs of active tuberculosis (Figure 2).

After a stay of 23 days, the patient was discharged with a prescription of anti-TB therapy, antivitamin K (started on day 15th of admission), and oral corticosteroids (prednisone) for 10 days with progressive degeneration and a basal bolus insulin regimen.

3. Discussion

Our patient presented a rare case of simultaneously diagnosed coinfection of COVID-19 and active pulmonary TB. This coinfection was described in both genders and in all age groups including a three-month-old Gambian patient, with a slight predominance in males and migrants [4]. These cases

were only reported in some countries like Italy [5–9], Singapore [10, 11], India [12–15], China [16–19], Brazil [20, 21], Turkey [22, 23], Saudi Arabia [24–26], and Mexico [27].

In Table 1, we describe clinical features and radiological findings as well as treatment options and outcome in our literature review of reported cases of this coinfection. The most common symptoms of COVID-19 include fever, cough, and dyspnea [56]. These symptoms are also common in TB infection [57] which makes TB diagnosis rather difficult and sometimes even delayed as in some cases. Our patient as well as multiple reported cases have presented unusual symptoms including night sweats, anorexia, weight loss, and hemoptysis (Table 1). These clinical features are typical of tuberculosis [57] and thus are important to look for when a patient presents respiratory complaints especially in high TB burden countries like ours.

In our case, the diagnosis of COVID-19 was confirmed by RT-PCR for SARS-CoV-2 done upon admission, systematically as per national protocols due to the ongoing pandemic. The complementary CT scan showed pulmonary condensation and diffused ground-glass opacities, commonly described in COVID-19 pneumonia [58]. It also revealed bilateral nodules and micronodules which are characteristic of an underlying active TB infection [59]. In the reported cases, other radiological findings suggesting TB

TABLE 1: Information on the reported cases.

Study	Country	Number of patients	Median age	Comorbidities	Clinical presentation	Radiological findings	Site of TB	COVID treatment	TB treatment	Mortality
Tadolini et al. [28]	Multicenter	49	49	8 COPD/asthma, 8 diabetes, 6 HIV, 5 kidney disease, 7 liver disease, 10 alcoholism, 20 smoking, 4 drug abuse	32 fever, 27 cough, 17 dyspnea	21 bilateral GGO, 23 cavitation, 25 infiltrates	36 pulmonary, 1 extrapulmonary, 12 both	22 HCQ, 12 antiviral therapy, 7 AZT, 1 other	NM	6 deaths
Gupta et al. [12]	India	22	44	3 diabetes, 4 hypertension, 2 seizure disorder, 1 hypothyroidism	22 fever, 11 cough, 7 dyspnea, 1 weight loss, 1 headache	14 bilateral infiltrates typical of COVID, 9 pulmonary fibrosis, 3 cavitations, 6 infiltrates/consolidation, 2 pleural effusion	17 pulmonary, 4 extrapulmonary, 1 disseminated	NM	21 (RIF, INH, PYR, ETB), 1 MDR therapy	6 deaths
Stochino et al. [5]	Italy	20	40	1 COPD, 4 diabetes, 1 psoriasis, 1 hypertension, 1 sickle cell disease	12 fever, 9 cough, 3 dyspnea, 3 chest pain, 2 headache, 1 conjunctivitis, 3 asymptomatic, 3 fever, 7 cough, 3 dyspnea, 4 headache, 1 anorexia, 1 hemoptysis, 1 skin rash, 4 asymptomatic, 3 fever, 3 cough, 1 chest pain, 2 dyspnea, 2 cough, 1 myalgia, 1 sore throat, 1 chest pain, 2 respiratory distress, 2 hemoptysis	1 GGO, 3 interstitial syndrome, 8 cavitations, 14 nodules, 1 pleural effusion, 1 calcification, 2 miliary	16 pulmonary, 1 extrapulmonary, 2 both, 1 disseminated	20 HCQ	14 (RIF, INH, PYR, ETB), 2 MDR therapy, 4 tailored therapy	1 death
Gül et al. [22]	Turkey	16	40.68	2 smoking, 2 asthma, 2 cardiac disease, 2 diabetes	9 GGO, 6 infiltration, 4 cavitations, 1 nodules, 1 pleural effusion	9 GGO, 6 infiltration, 4 cavitations, 1 nodules, 1 pleural effusion	9 pulmonary, 5 extrapulmonary, 1 both	10 HCQ, 8 FAV	13 (RIF, INH, PYR, ETB), 1 (RIF, INH, PYR, STR), 1 (RIF, INH, STR, ETB)	1 death
He et al. [16]	China	3	56.3	2 smoking	3 GGO, 1 chest pain, 2 dyspnea, 2 cough, 1 myalgia, 1 sore throat, 1 chest pain, 2 respiratory distress, 2 hemoptysis	3 GGO, 1 cavitation	3 pulmonary	3 LOP/RIT, Arbidol	1 (RIF, INH, PYR, ETB)	0
Liu et al. [17]	China	3	40	1 MDR-TB, 1 <i>Aspergillus</i> infection		3 GGO	3 pulmonary	1 AZT, 3 Arbidol, 3 MOX, 2 LNZ	1 (ETB/PYR/AMK/LEV), 1 CS, 1 CFZ, 1 LNZ	0

TABLE 1: Continued.

Study	Country	Number of patients	Median age	Comorbidities	Clinical presentation	Radiological findings	Site of TB	COVID treatment	TB treatment	Mortality
Yao et al. [18]	China	3	50.3	2 smoking, 1 diabetes	3 fever, 3 cough, 3 weight loss, 1 night sweat	3 GGO, 2 pleural effusion	3 pulmonary	2 LOP/RIT, 1 UMF HCL, 2 IFN- α	2 RIF, INH, PYR, ETB	1 death
Cao et al. [19]	China	1	47	Asthma	Unwellness, poor appetite	Cavern calcification	Pulmonary	LOP/RIT	RIF, INH, PYR, ETB	0
Tham et al. [10]	Singapore	4	31.75	NM	4 fever, 4 cough, 1 dyspnea, 1 weight loss	1 GGO, 1 cavitation, 2 pleural effusion, 3 consolidations	4 pulmonary	NM	4 RIF, INH, PYR, ETB	0
Al Lawat et al. [29]	Oman	2	49	1 smoking, 1 diabetes, 1 hypertension	2 fever, 2 cough, 1 dyspnea, 1 chest pain, 1 headache, 1 weight loss	1 cavitations, 2 nodules	2 pulmonary	2 CTX, CLR, and OSE, 2 HCQ, 1 LOP/RIT	2 RIF, INH, PYR, ETB	0
Gadelha Farias et al. [20]	Brazil	2	41	1 HIV, 1 hepatitis B	1 fever, 1 cough, 2 respiratory distress, 1 headache, 1 hemoptysis	2 GGO, 1 cavitation	2 pulmonary	2 HCQ, 2 AZT, 2 CTX	2 RIF, INH, PYR, ETB	0
Yousaf et al. [30]	Qatar	6	35.5	1 diabetes mellitus	3 fever, 5 cough, 2 myalgia, 2 headache, 5 weight loss	6 infiltrations, 6 cavitation, 1 pleural effusion	6 pulmonary	6 (HCQ, AZT, CTX)	6 (RIF, INH, PYR, ETB)	NM
Shabrawishi et al. [24]	Saudi Arabia	7	34.8	1 HIV	7 fever, 6 cough, 2 hemoptysis, 4 night sweats, 6 anorexia, 6 weight loss	1 GGO, 7 consolidation, 3 cavitations, 2 nodules, 1 pleural effusion, 1 pneumothorax	6 pulmonary, 1 both	4 (AZT, CTX), 1 HCQ, 1 (RIF, INH, LOP/RIT)	7 RIF, INH, PYR, ETB	1 death
Khayat et al. [25]	Saudi Arabia	1	40	None	Fever, cough, body aches, chest pain, anorexia	Consolidation	Pulmonary	NM	RIF, INH, PYR, ETB	0

TABLE 1: Continued.

Study	Country	Number of patients	Median age	Comorbidities	Clinical presentation	Radiological findings	Site of TB	COVID treatment	TB treatment	Mortality
Baskara et al. [31]	Indonesia	1	42	Diabetes	Dizziness, headache, cough, abdominal pain, night sweats	GGO	Pulmonary	AZT, CTX, CTZ, HCQ, OSE	RIF, INH, PYR, ETB	0
Vilbrun et al. [32]	Haiti	1	26	MDR-TB	Fever, cough, dyspnea, weight loss	Cavitation Consolidation	Pulmonary	NM	BDQ, LEV, LNZ, CFZ, PYR	0
Luciani et al. [6]	Italy	1	32	BCG vaccination	Fever, myalgia	Consolidation pleural effusion	Pulmonary	LOP/RIT, HCQ, LNZ, CLR, T2P	RIF, INH, PYR, ETB	0
Musso et al. [7]	Italy	1	45	Immunosuppression, alcoholism	Fever, cough, fatigue, weight loss, respiratory failure.	GGO, cavitation, hydropneumothorax, atelectasis	Pulmonary	HCQ, corticosteroids	RIF, INH, ETB, PYR, AMK, MOX	Death
Lovino et al. [8]	Italy	1	45	None	Fever, productive cough, hemoptysis, myalgia	GGO, excavated consolidation	Pulmonary	NM	NM	0
Rivas et al. [33]	Panama	2	41	2 HIV	2 fever, 1 cough, 2 dyspnea, 1 weight loss	2 infiltrations	Pulmonary	2 AZT, 2 HCQ, 1 CTX, 1 LEV, 1 antiviral therapy	2 RIF, INH, PYR, ETB	0
Pozdnyakov et al. [34]	Canada	1	64	Diabetes, hypertension, and dyslipidemia	Dyspnea, respiratory distress syndrome	GGO, interstitial syndrome	Pulmonary	CTX	RIF, INH, PYR, ETB	1 death
Faqihi et al. [26]	Saudi Arabia	1	60	Diabetes, hypertension	Fever, cough, chest pain, respiratory distress,	GGO	Pulmonary	LOP/RIT, RIB, DEX	RIF, INH, PYR, ETB	0
Starshinova et al. [35]	Russia	1	59	Heart disease, COPD, emphysema, tuberculosis	Fever, rhinitis, cough, shortness of breath	GGO, infiltration, consolidation, pneumothorax, emphysema	Pulmonary	CTX, LEV, AZT	RIF, INH, PYR, ETB	0
Orozco et al. [27]	Mexico	1	51	Diabetes	Anosmia, dysgeusia, cough, dyspnea	GGO cavitation	Pulmonary	Oxygenotherapy	RIF, INH, PYR, ETB	0

TABLE 1: Continued.

Study	Country	Number of patients	Median age	Comorbidities	Clinical presentation	Radiological findings	Site of TB	COVID treatment	TB treatment	Mortality
Marwah et al. [13]	India	1	34	MDR tuberculosis, chronic hepatitis B	Productive cough, dyspnea, weight loss, fever, respiratory failure Fever, productive cough, cough, chest pain, dyspnea, night sweats, respiratory distress.	Cavitation nodules	Pulmonary	Corticosteroids, oxygenotherapy	RIF, INH, ETB, PYR, BDQ	0
Patil and Gondhali [14]	India	1	75	Ex-smoker	Fever, productive cough, cough, chest pain, dyspnea, weight loss, hemoptysis.	GGO, cavitation infiltrates	Pulmonary	Remdesivir, corticosteroids, anticoagulation	RIF, INH, ETB, PYR	0
Yadav and Rawal [15]	India	1	43	None	Fever, productive cough, chest pain, dyspnea, night sweats, respiratory distress.	Bilateral consolidation	Pulmonary	NM	RIF, INH, ETB, PYR	0
Yadav et al. [36]	India	1	26	None	Fever, productive cough, chest pain, dyspnea, hemoptysis, weight loss, anorexia.	Consolidation	Pulmonary	NM	INH, ETB, PYR, kanamycin, MOX, CFZ, ethionamide	0
Jacob et al. [37]	India	1	20	Multiple sclerosis	Fever, productive cough, weight loss	Opacity	Pulmonary	Corticosteroids, oxygenotherapy, antibiotics	RIF, INH, ETB, PYR	0
Ata et al. [38]	India	1	28	Glioma	Dizziness, headache, vomiting Fever, cough, dyspnea, hemoptysis, respiratory distress	GGO nodules	Pulmonary with CNS involvement	HCCQ, AZT	RIF, INH, PYR, ETB, pyridoxine	0
Goel Sharma et al. [39]	India	1	53	Diabetes chronic kidney disease	Fever, cough, dyspnea, hemoptysis, respiratory distress	GGO, consolidation, fibrosis	Pulmonary	Ampicillin, AZT, HCQ	RIF, INH, PYR, ETB	0

TABLE 1: Continued.

Study	Country	Number of patients	Median age	Comorbidities	Clinical presentation	Radiological findings	Site of TB	COVID treatment	TB treatment	Mortality
Singh et al. [40]	India	1	76	Hypertension	Fever, respiratory distress, cough, anorexia, weight loss Fever, productive cough, hemoptysis, anorexia, taste and smell disorders	GGO Consolidation, pleural effusion	Pulmonary	AZT, HCQ, corticosteroids	RIF, INH, PYR, ETB	0
Sahara and Yokota [41]	Japan	1	59	None	Fever, dyspnea, headache, cachexia, respiratory distress	GGO, tree-in-bud pattern	Pulmonary	NM	RIF, INH, ETB, PYR	0
Ortiz-Martínez et al. [42]	Colombia	1	34	HIV drug use, anxiety disorder	Fever, cough, dyspnea, general status alteration, weight loss, night sweats	GGO, miliary, pleural effusion	Pulmonary	SAM, DOX, corticosteroids, oxygenotherapy	NM	Death
Aissaoui et al. [43]	French Guiana	1	30	NM	Fever, cough, dyspnea, general status alteration, weight loss, night sweats	Consolidation, tree-in-bud pattern	Pulmonary	CTX, DOX	RIF, INH, ETB, PYR	0
Bouaré et al. [44]	Morocco	1	32	HIV	Fever cough, headache, myalgia.	Miliary	Pulmonary	HCQ, AZT	RIF, INH, ETB, PYR	0
Cutler et al. [45]	USA	1	61	Parkinson	Fever, cough, hemoptysis	Pleural effusion, atelectasis	Pulmonary	HCQ, oxygenotherapy AMX, HCQ, AZT,	RIF, INH, ETB, PYR	0
Freij et al. [46]	USA	1	5	Group A streptococcal pharyngitis	Fever, headache	Clear	Extrapulmonary	corticosteroids, remdesivir	None	Death
Butt et al. [47]	UK	1	42	None	Dyspnea fever, dry cough, fatigue	GGO, Pleural effusion, Consolidation	Pulmonary	DEX, remdesivir	RIF, INH, ETB, PYR	0
Çinar et al. [23]	Turkey	1	55	Myelodysplastic disease, kidney disease, <i>Klebsiella pneumoniae</i> infection	Fever, cough, dyspnea	GGO	Disseminated	Plasma therapy, FAV, TCZ, meropenem	RIF, INH, PYR, ETB	0

TABLE 1: Continued.

Study	Country	Number of patients	Median age	Comorbidities	Clinical presentation	Radiological findings	Site of TB	COVID treatment	TB treatment	Mortality
Tolossa et al. [48]	Ethiopia	1	55	HIV	Fever productive cough, headache, chest pain, dyspnea, night sweats, weight loss, anorexia, fatigue, hemoptysis Fever productive cough, dyspnea, night sweats, weight loss, anosmia, headache, myalgia, episodes of loss of consciousness. Fever, chest pain, productive cough, dyspnea.	Patchy opacities	Pulmonary	Cefepime, corticosteroids	RIF, INH, PYR, ETB	0
Bongomin et al. [49]	Uganda	1	37	HIV, cryptococcal meningitis		GGO, miliary	Disseminated	TZP, corticosteroids, oxygenation	None	Death
Wong et al. [11]	Singapore	1	47	None		Opacities cardiomegaly	Extrapulmonary (pericardiac)	Remdesivir, oxygenotherapy	RIF, INH, PYR, ETB	0
Kozinska and Augustynowicz-Kopeć [50]	Poland	2	67.5	1 smoking, 1 HIV, 1 atrial fibrillation, 1 renal insufficiency, 2 treated pulmonary TB, treated urogenital TB	1 (cough, fever, dyspnea, sore throat), 1 no data	1 (atelectasis pleural effusion), 1 no data	1 pulmonary, 1 disseminated	No data	1 (RIF, INH, PYR, ETB), 1 no data	1 death
Gerstein et al. [51]	USA	1	49	Alcoholism cirrhosis	Fever, dry cough, orthopnea, abdominal pain	Pleural effusion, opacities	Disseminated	HCO, plasma infusion	RIF, INH, ETB, LEV	0
Mulale et al. [52]	Botswana	1	3 months	None	Fever, cough, respiratory distress, failure to thrive	Infiltrates, opacities, consolidations	Disseminated	Ampicillin, gentamicin, oxygenotherapy	RIF, INH, PYR, ETB	Death

TABLE 1: Continued.

Study	Country	Number of patients	Median age	Comorbidities	Clinical presentation	Radiological findings	Site of TB	COVID treatment	TB treatment	Mortality
Essajee et al. [53]	South Africa	1	2 y 7 months	Cerebral venous thrombosis	Lethargy, hemiplegia, respiratory distress	Miliary	Disseminated	Corticosteroids, oxygenotherapy, antibiotics	RIF, INH, PYR, ethionamide, corticosteroids	0
Brandi et al. [9]	Italy	1	78	Bladder cancer, BCG intravesical instillation, diabetes, COPD, abdominal aortic aneurysm	Fever, cough, dysuria, dyspnea, respiratory distress	GGO, miliary	Disseminated	NM	RIF, INH, ETB	Death
Osejo-Betancourt et al. [54]	Colombia	1	71	Smoking	Fever, dry cough, dyspnea, malaise, anosmia, dysgeusia	Bilateral alveolar opacities, cavitation, consolidation, nodules	Pulmonary	DEX, SAM, oxygenotherapy	RIF, INH, PYR, ETB	0
Pinheiro et al. [21]	Brazil	1	68	Diabetes, hypertension, chronic liver disease	Fever dyspnea, cough,	GGO, opacities, consolidations	Pulmonary	NM	NM	NM
Orozco et al. [27]	Mexico	1	51	Diabetes	Anosmia, dysgeusia, nocturnal diaphoresis, cough, respiratory distress, 2 fever, 2 cough, 2 weight loss, 1 respiratory distress, 1 sore throat.	GGO, cavitation, nodules	Pulmonary	Oxygenotherapy	RIF, INH, PYR, ETB	0
Gbenga et al. [55]	Nigeria	2	31.5	None	respiratory distress, 1 sore throat.	1 reticulonodular infiltrates, 1 opacity	Pulmonary	2 AZT, 2 LOP/RIT, 2 (Vit C, zinc sulfate, prednisone)	2 RIF, 2 INH, 2 PYR, 2 ETB	0

infection included infiltrates, consolidation, cavitation, pleural effusion, miliary, and calcification (Table 1). These previous aspects are atypical of COVID-19 and their presence signs a TB coinfection [59] in need of further confirmatory tests.

The TB diagnosis in our case was first brought up by the atypical CT scan findings and was later confirmed by GeneXpert MTB/RIF assay and sputum cultures coming back positive for drug susceptible M.tb (*Mycobacterium tuberculosis*) like most of the reported cases (Table 1). However, drug resistance was reported in some cases (Table 1).

In our case, we noted lymphocytopenia, neutrophilia, increased inflammatory markers (CRP and ferritinemia), and LDH which was described in COVID-19 infection and linked to severe disease and higher mortality [60]. On the same note, an elevated D-dimers level was also related to worse prognosis and to high probability of coagulopathy [60]; although not measured in our case, they would have been elevated since our patient had already presented thrombotic complications.

Although thrombotic complications are frequent in COVID-19 infection, their exact incidence has not yet been determined. However, it is noted that their rate is higher in critically ill COVID-19 patients admitted to ICU wards in comparison to non-ICU patients [61]. Their pathogenesis could mainly be related to local factors including inflammation and immunothrombosis induced by the viral infection and/or to the usual thrombotic factors such as prolonged bed rest, age, and certain comorbidities [61, 62]. Our patient has presented PE complicating DVT, but studies show that PE could occur independently from DVT which supports the hypothesis of in situ thrombosis mechanism [61, 62]. Fortunately, our patient has made an uneventful recovery, but these complications and specifically PE are considered independent factors of morbidity and mortality in COVID-19 patients [63], highlighting the importance of the close monitoring and the development of prophylactic anticoagulation protocols especially for critically ill patients.

There is still no consensus considering the treatment of COVID-19 and tuberculosis coinfection. Our patient received the classic quadruple antituberculosis regimen (isoniazid + rifampicin + pyrazinamide + ethambutol) along with broad spectrum antibiotics for the COVID-19 pneumonia as per the national protocol in Morocco. In the cohort of Tadolini et al., while the antitubercular treatment was the same for drug susceptible M.tb, the reported treatment for COVID-19 was of different combinations of hydroxychloroquine, azithromycin, and lopinavir/ritonavir: 17 patients received a monotherapy, 9 a combination of two drugs, and 2 received 3 or more drugs [28]. Antiretroviral therapy and hydroxychloroquine are empirically used for COVID-19 treatment; however, they were shown to have interaction with antitubercular drugs, especially rifampicin, isoniazid, and second-line treatments [64]. Since these drug interactions have not been fully elucidated, their use in our case was avoided.

The use of corticosteroids in COVID-19 is recommended in certain cases to modulate the inflammatory

process as in our national COVID-19 protocol. Many cases in literature suggest the possibility of TB reactivation under these immunosuppressive treatments [65], but due to limited data, no conclusion can be drawn about this subject. Recommendations are to administer corticosteroids in a low dose and for a short period of time when it is indicated to avoid inducing immunosuppression and risk opportunistic infections such as TB [66].

In the study by Tadolini et al., 9 patients had both diseases diagnosed within the same week including 4 on the same day, and 14 had COVID-19 first [28]. However, the authors failed to show the role of COVID-19 in the progression of TB due to the study limitations. The relationship between COVID-19 and the onset of TB infection is still debatable, but it seems to be bidirectional. Since both infections depend on cellular immunity, temporary immunosuppression caused by SARS-CoV-2 increases susceptibility for new TB infections or reactivation of latent TB infections and vice versa [34].

In the same cohort, the mortality rate was as high as 6/49 (12.3%) and was reported in aging patient with 1 or plus comorbidities [28]. The risk factors for this coinfection are comparable to those of TB without COVID-19 including age, COPD, HIV, smoking, diabetes, hypertension, and renal failure. Our patient checked two of these factors, those of age and diabetes, and fortunately presented a moderate pneumonia that did not require intensive care with a favorable evolution.

In conclusion, the possible overlap of symptoms of COVID-19 and TB must alert clinicians to think of TB coinfection when confronted with atypical clinical or radiological presentations, especially in migrants and high TB burden countries. Larger studies are needed to fully to explore and establish clear treatment and prevention protocols for this coinfection.

Written informed consent was obtained from the patient for using images and other relevant data for publication in this study.

4. Conclusion

In the mist of the ongoing pandemic, as all resources are being allocated to the fight against COVID-19, the emerging cases of COVID-19 and TB coinfection is ought to remind us of an evenly important fight, that against TB. Therefore, we strongly recommend testing for both diseases when faced with respiratory symptoms especially in high TB burden countries like ours or at least before atypical clinical or radiological presentations. The available data about these cases is limited still, and further studies are necessary to better comprehend the effects of COVID-19 on TB and vice versa.

Abbreviations

NM:	Not mentioned
MDR:	Multidrug resistant
COPD:	Chronic obstructive pulmonary disease
GGO:	Ground-glass opacities

HCQ:	Hydroxychloroquine
AZT:	Azithromycin
FAV:	Favipiravir
LOP/RIT:	Lopinavir/ritonavir
MOX:	Moxifloxacin
LNZ:	Linezolid
UMF HCL:	Umifenovir hydrochloride
IFN- α :	Interferon- α
TZP:	Piperacillin-tazobactam
CTX:	Ceftriaxone
CLR:	Clarithromycin
OSE:	Oseltamivir
CTZ:	Ceftazidime
SAM:	Ampicillin-sulbactam
DOX:	Doxycycline
DEX:	Dexamethasone
TCZ:	Tocilizumab
RIB:	Ribavirin
RIF:	Rifampicin
INH:	Isoniazid
PYR:	Pyrazinamide
ETB:	Ethambutol
STR:	Streptomycin
AMK:	Amikacin
LEV:	Levofloxacin
CS:	Cycloserine
BDQ:	Bedaquiline
CFZ:	Clofazimine.

Data Availability

The data supporting this case report are from previously reported studies and datasets, which have been cited. The patient's personal data are available from the corresponding author upon request and cannot be disclosed publicly due to the patient privacy policy of our institution.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

- [1] World Health Organization, "Director-general's opening remarks at the media briefing on COVID-19 on 11 march 2020," 2020, <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>.
- [2] World Health Organization, *10 Facts on Tuberculosis*, 2021, <https://www.who.int/news-room/facts-in-pictures/detail/tuberculosis>.
- [3] Z. F. Udawadia, A. Vora, A. R. Tripathi, K. N. Malu, C. Lange, and R. Sara Raju, "COVID-19-Tuberculosis interactions: when dark forces collide," *Indian Journal of Tuberculosis*, vol. 67, no. 4, pp. S155–S162, 2020.
- [4] A. Mishra, A. A. George, K. K. Sahu, A. Lal, and G. Abraham, "Tuberculosis and COVID-19 Co-infection: an updated review," *Acta Bio-Medica: Atenei Parmensis*, vol. 92, 2020.
- [5] C. Stochino, S. Villa, P. Zucchi, P. Parravicini, A. Gori, and M. C. Raviglione, "Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital," *European Respiratory Journal*, vol. 56, 2020.
- [6] M. Luciani, E. Bentivegna, V. Spuntarelli et al., "Coinfection of tuberculosis pneumonia and COVID-19 in a patient vaccinated with bacille calmette-guérin (BCG): case report," *SN Comprehensive Clinical Medicine*, vol. 2, 2020.
- [7] M. Musso, F. D. Gennaro, G. Gualano et al., "Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy: a case report," *Infection*, vol. 49, pp. 1061–1064, 2020.
- [8] M. Iovino, M. Caruso, A. Corvino et al., "Latent tuberculosis reactivation in the setting of SARS-Cov-2 infection: the analysis of the radiologic features that help the diagnosis," *Radiology Case Reports*, vol. 17, 2022.
- [9] N. Brandi, L. Bartalena, C. Mosconi, and R. Golfieri, "A unique case of miliary pulmonary tuberculosis induced by bacillus Calmette-Guérin intravesical instillation with COVID-19 superinfection," *South African Journal of Radiology*, vol. 25, 2021.
- [10] S. M. Tham, W. Y. Lim, C. K. Lee et al., "Four patients with COVID-19 and tuberculosis, Singapore, april-may 2020," *Emerging Infectious Diseases*, vol. 26, 2020.
- [11] S. W. Wong, J. K. X. Ng, and Y. W. Chia, "Tuberculous pericarditis with tamponade diagnosed concomitantly with COVID-19: a case report," *European Heart Journal—Case Reports*, vol. 5, 2021.
- [12] N. Gupta, P. Ish, A. Gupta et al., "A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis," *European Respiratory Journal*, vol. 56, 2020.
- [13] V. Marwah, D. K. Peter, T. Ajai Kumar, G. Bhati, and A. Kumar, "Multidrug-resistant tuberculosis in COVID-19: double trouble," *Medical Journal Armed Forces India*, vol. 77, 2021.
- [14] S. Patil and G. Gondhali, "COVID-19 pneumonia with pulmonary tuberculosis: double trouble," *International Journal of Mycobacteriology*, vol. 10, no. 2, pp. 206–209, 2021.
- [15] S. Yadav and G. Rawal, "The case of pulmonary tuberculosis with COVID-19 in an Indian male—a first of its type case ever reported from South Asia," *Pan African Medical Journal*, vol. 36, p. 374, 2020.
- [16] G. He, J. Wu, J. Shi et al., "COVID-19 in tuberculosis patients: a report of three cases," *Journal of Medical Virology*, vol. 92, 2020.
- [17] C. Liu, Y. Yu, J. Fleming et al., "Severe COVID-19 cases with a history of active or latent tuberculosis," *International Journal of Tuberculosis & Lung Disease*, vol. 24, 2020.
- [18] Z. Yao, J. Chen, Q. Wang et al., "Three patients with COVID-19 and pulmonary tuberculosis, wuhan, China, january-february 2020," *Emerging Infectious Diseases*, vol. 26, 2020.
- [19] B. Cao, M. Wei, Y. Du, K. Xiao, Q. Li, and W. Lu, "Coronavirus disease 2019 with comorbid pulmonary tuberculosis: a case report," *Iranian Red Crescent Medical Journal*, vol. 22, p. 22, 2020.
- [20] L. A. B. Gadelha Farias, A. L. Gomes Moreira, E. Austregésilo Corrêa et al., "Case report: coronavirus disease and pulmonary tuberculosis in patients with human immunodeficiency virus: report of two cases," *The American Journal of Tropical Medicine and Hygiene*, vol. 103, 2020.
- [21] D. O. Pinheiro, M. S. L. Pessoa, C. F. C. Lima, and J. L. B. Holanda, "Tuberculosis and coronavirus disease 2019 coinfection," *Revista da Sociedade Brasileira de Medicina Tropical*, vol. 53, 2020.
- [22] Ş Gül, E. S. Akalın Karaca, E. Y. Özgün Niksarlıoğlu, H. Çınarka, and M. A. Uysal, "Coexistence of tuberculosis and COVID-19 pneumonia: a presentation of 16 patients from

- Turkey with their clinical features,” *Tuberk Toraks*, vol. 70, 2022.
- [23] O. E. Çınar, B. Sayınalp, E. Aladağ Karakulak et al., “Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis,” *Transfusion and Apheresis Science*, vol. 59, 2020.
- [24] M. Shabrawishi, A. AlQarni, M. Ghazawi et al., “New disease and old threats: a case series of COVID-19 and tuberculosis coinfection in Saudi Arabia,” *Clinical Case Reports*, vol. 9, 2021.
- [25] M. Khayat, H. Fan, and Y. Vali, “COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: a case report,” *Respiratory Medicine Case Reports*, vol. 32, 2021.
- [26] F. Faqih, A. Alharthy, A. Noor, A. Balshi, A. Balhamar, and D. Karakitsos, “COVID-19 in a patient with active tuberculosis: a rare case-report,” *Respiratory Medicine Case Reports*, vol. 31, 2020.
- [27] J. A. Martínez Orozco, Á Sánchez Tinajero, E. Becerril Vargas et al., “COVID-19 and tuberculosis coinfection in a 51-year-old taxi driver in Mexico city,” *American Journal of Case Reports*, vol. 21, 2020.
- [28] M. Tadolini, J. M. García, F. X. Blanc et al., “On tuberculosis and COVID-19 co-infection,” *European Respiratory Journal*, vol. 56, 2020.
- [29] R. Al Lawati, N. Al Busaidi, R. Al Umairi, M. Al Busaidy, H. H. Al Naabi, and F. Khamis, “COVID-19 and pulmonary Mycobacterium tuberculosis coinfection,” *Oman Medical Journal*, vol. 36, 2021.
- [30] Z. Yousaf, A. A. Khan, H. A. Chaudhary et al., “Cavitary pulmonary tuberculosis with COVID-19 coinfection,” *ID Cases*, vol. 22, 2020.
- [31] M. A. Baskara, F. Makrufardi, and A. Dinisari, “COVID-19 and active primary tuberculosis in a low-resource setting: a case report,” *Annals of Medicine and Surgery*, vol. 62, pp. 80–83, 2021.
- [32] S. C. Vilbrun, L. Mathurin, J. W. Pape, D. Fitzgerald, and K. F. Walsh, “Case report: multidrug-resistant tuberculosis and COVID-19 coinfection in port-au-prince, Haiti,” *The American Journal of Tropical Medicine and Hygiene*, vol. 103, no. 5, 2020.
- [33] N. Rivas, M. Espinoza, A. Loban et al., “Case report: COVID-19 recovery from triple infection with Mycobacterium tuberculosis, HIV, and SARS-CoV-2,” *The American Journal of Tropical Medicine and Hygiene*, vol. 103, 2020.
- [34] A. Pozdnyakov, A. Jin, and M. Bader, “Reactivation of pulmonary tuberculosis in a patient with COVID-19,” *Infectious Diseases in Clinical Practice*, vol. 29, 2021.
- [35] A. Starshinova, L. Guglielmetti, O. Rzhepishevskaya, O. Ekaterincheva, Y. Zinchenko, and D. Kudlay, “Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical case),” *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, vol. 24, 2021.
- [36] S. Yadav and G. Rawal, “Primary multidrug-resistant pulmonary tuberculosis with a concomitant COVID-19 infection in an Indian female-world’s first case of its type in this current pandemic,” *Journal of Family Medicine and Primary Care*, vol. 10, 2021.
- [37] J. Jacob, R. Venkataram, and G. B. Hosmane, “Coinfection of SARS-CoV-2 and MTB: how not to miss the wood for the trees,” *BMJ Case Reports*, vol. 14, no. 7, 2021.
- [38] F. Ata, Q. Yousaf, J. Veliyankodan Parambil, J. Parengal, M. G. Mohamedali, and Z. Yousaf, “A 28-year-old man from India with SARS-cov-2 and pulmonary tuberculosis Co-infection with central nervous system involvement,” *The American journal of case reports*, vol. 21, 2020.
- [39] S. Goel Sharma, R. K. Yadav Sherawat, J. Sharma, S. Sherawat, S. Sharma, and R. Sherawat, “COVID-19 pneumonia with delayed viral clearance in a patient with active drug-resistant pulmonary tuberculosis,” *Indian Journal of Critical Care Medicine*, vol. 24, 2020.
- [40] A. Singh, A. Gupta, and K. Das, “Severe acute respiratory syndrome coronavirus-2 and tuberculosis coinfection: double trouble,” *Indian Journal of Medical Specialities*, vol. 11, 2020.
- [41] T. Sahara and K. Yokota, “Concurrent COVID-19 and tuberculosis in an immigrant worker presenting with hemoptysis,” *The American Journal of Tropical Medicine and Hygiene*, vol. 105, 2021.
- [42] Y. Ortiz-Martinez, J. M. Mogollón-Vargas, M. López-Rodríguez, and A. J. Rodríguez-Morales, “A fatal case of triple coinfection: COVID-19, HIV and Tuberculosis,” *Travel Medicine and Infectious Disease*, vol. 43, 2021.
- [43] H. Aissaoui, D. Louvel, and K. Drak Alsibai, “SARS-CoV-2 and Mycobacterium tuberculosis coinfection: a case of unusual bronchoesophageal fistula,” *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, vol. 24, 2021.
- [44] F. Bouaré, M. Laghmari, F. N. Etouche et al., “Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with chloroquine and rifampin,” *Pan African Medical Journal*, vol. 35, no. Suppl 2, p. 110, 2020.
- [45] T. Cutler, D. Scales, W. Levine, N. Schluger, and M. A. O’Donnell, “A novel viral epidemic collides with an ancient scourge: COVID-19 associated with tuberculosis,” *American Journal of Respiratory and Critical Care Medicine*, vol. 202, no. 5, pp. 748-749, 2020.
- [46] B. J. Freij, B. M. Gebara, R. Tariq et al., “Fatal central nervous system co-infection with SARS-CoV-2 and tuberculosis in a healthy child,” *BMC Pediatrics*, vol. 20, 2020.
- [47] M. F. Butt, M. Symonds, and R. Khurram, “Tension hydrothorax in a patient with SARS-CoV-2 pneumonitis and pleural Mycobacterium tuberculosis,” *BMJ Case Reports*, vol. 14, 2021.
- [48] T. Tolossa, R. Tsegaye, S. Shiferaw et al., “Survival from a triple co-infection of COVID-19, HIV, and tuberculosis: a case report,” *International Medical Case Reports Journal*, vol. 14, 2021.
- [49] F. Bongomin, S. G. Sereke, J. Okot et al., “COVID-19, HIV-associated cryptococcal meningitis, disseminated tuberculosis and acute ischaemic stroke: a fatal foursome,” *Infection and Drug Resistance*, vol. 14, 2021.
- [50] M. Kozłńska and E. Augustynowicz-Kopeć, “COVID-19 in patients with active tuberculosis,” *Diagnostics*, vol. 11, 2021.
- [51] S. Gerstein, A. Khatri, N. Roth, and F. Wallach, “Coronavirus disease 2019 and extra-pulmonary tuberculosis co-infection - a case report and review of literature,” *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, vol. 22, 2021.
- [52] U. K. Mulale, T. Kashamba, J. Stryzko, and L. T. Kyokunda, “Fatal SARS-CoV-2 and Mycobacterium tuberculosis coinfection in an infant: insights from Botswana,” *BMJ Case Reports*, vol. 14, 2021.
- [53] F. Essajee, R. Solomons, P. Goussard, and R. Van Toorn, “Child with tuberculous meningitis and COVID-19 coinfection complicated by extensive cerebral sinus venous thrombosis,” *BMJ Case Reports*, vol. 13, 2020.
- [54] M. Osejo-Betancourt, S. Molina-Paez, and M. Rubio-Romero, “Pulmonary tuberculosis and COVID-19 coinfection: a new

- medical challenge,” *Monaldi Archives for Chest Disease*, vol. 92, 2021.
- [55] T. A. Gbenga, T. Oloyede, O. R. Ibrahim, A. Sanda, and B. M. Suleiman, “Pulmonary tuberculosis in coronavirus disease-19 patients: a report of two cases from Nigeria,” *Open Access Macedonian Journal of Medical Sciences*, vol. 8, 2020.
- [56] S. Umakanthan, P. Sahu, A. V. Ranade et al., “Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19),” *Postgraduate Medical Journal*, vol. 96, 2020.
- [57] World Health Organization, *Systematic Screening for Active Tuberculosis: An Operational Guide*, World Health Organization, Geneva, Switzerland, 2015.
- [58] Z. Ye, Y. Zhang, Yi Wang, Z. Huang, and B. Song, “Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review,” *European Radiology*, vol. 30, 2020.
- [59] A. C. Nachiappan, K. Rahbar, X. Shi et al., “Pulmonary tuberculosis: role of radiology in diagnosis and management,” *RadioGraphics*, vol. 37, 2017.
- [60] A. Pourbagheri-Sigaroodi, D. Bashash, F. Fateh, and H. Abolghasemi, “Laboratory findings in COVID-19 diagnosis and prognosis,” *Clinica Chimica Acta*, vol. 510, 2020.
- [61] Y. J. Suh, H. Hong, M. Ohana et al., “Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis,” *Radiology*, vol. 298, 2021.
- [62] L. Roncon, M. Zuin, S. Barco et al., “Incidence of acute pulmonary embolism in COVID-19 patients: systematic review and meta-analysis,” *European Journal of Internal Medicine*, vol. 82, 2020.
- [63] F. Scudiero, A. Silverio, M. Di Maio et al., “Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome,” *Thrombosis Research*, vol. 198, 2021.
- [64] L. Thomas, S. R. Birangal, R. Ray et al., “Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data,” *Therapeutic Advances in Drug Safety*, vol. 12, 2021.
- [65] A. H. Alzeer and J. M. FitzGerald, “Corticosteroids and tuberculosis: risks and use as adjunct therapy,” *Tubercle and Lung Disease*, vol. 74, 1993.
- [66] R. Gopaldaswamy and S. Subbian, “Corticosteroids for covid-19 therapy: potential implications on tuberculosis,” *International Journal of Molecular Sciences*, vol. 22, 2021.